Theralase(R) Closes $1.1 M Non-Brokered Private Placement
MWN-AI** Summary
Theralase® Technologies Inc. (TSXV: TLT) has successfully closed a non-brokered private placement, raising $1.1 million through the issuance of 4,230,770 units at a price of $0.26 per unit. Each unit comprises one common share and a warrant that allows the holder to purchase an additional share at $0.36 for five years. The funds will primarily support the ongoing Phase II clinical study for Non-Muscle Invasive Bladder Cancer (NMIBC), alongside general working capital and corporate purposes.
The company emphasized that the securities issued will not be registered under the U.S. Securities Act and cannot be sold in the U.S. or to U.S. persons unless a registration exemption applies. The issued securities are subject to a hold period until July 11, 2026, adhering to Canadian securities law.
Insider transactions were also noted, with certain insiders acquiring 100,000 units for total proceeds of $26,000, categorized as a related party transaction under relevant securities regulations. The company is exempt from formal valuation requirements and minority shareholder approval for these insider subscriptions, as their total value does not exceed 25% of the company's market capitalization.
Theralase® focuses on the development of energy-activated small molecules aimed at the destruction of cancer cells, bacteria, and viruses. As a clinical stage pharmaceutical entity, it navigates various risks associated with funding, regulatory approvals, and market performance that could impact its operations. Forward-looking statements in this announcement highlight the uncertainties and risks surrounding the successful development of its drug formulations and their market commercialization, urging readers not to overly rely on these projections.
For further information, Theralase® invites prospective investors to reach out through their provided contact details.
MWN-AI** Analysis
Theralase® Technologies Inc. (TSXV: TLT) has recently completed a successful non-brokered private placement, raising approximately CAD 1.1 million through the issuance of 4,230,770 Units. Each Unit comprises one common share and one warrant, which can be exercised at CAD 0.36 per share within the next five years. This financing is strategically designed to accelerate their Phase II clinical study for Non-Muscle Invasive Bladder Cancer (NMIBC), along with addressing working capital and corporate expenses.
From a market perspective, investors should assess Theralase’s positioning in the burgeoning oncology sector. The company's focus on energy-activated small molecules for treating cancer highlights its innovation potential, especially as the demand for effective cancer therapies continues to rise. Currently, Theralase's share price stands at CAD 0.26, indicating a potential upside for investors, given the warrant exercise price of CAD 0.36. Should clinical trials yield positive results, market sentiment could significantly shift, boosting the stock price beyond current levels.
However, prospective investors should remain cautious due to the inherent risks associated with early-stage pharmaceutical investments. The company's clinical trials must secure regulatory approvals, and there is no guarantee that their treatment will effectively address NMIBC or other targeted conditions. Additionally, the four-month hold period on securities from this offering requires investors to consider liquidity constraints in the near term.
The insider participation in this placement (100,000 Units) may signal confidence in the company's direction, yet it can also be seen as a cautionary sign regarding the need for cash flow. Overall, while Theralase presents intriguing opportunities within the oncology sector, careful consideration of both risks and prospective rewards is advised before making investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Toronto, Ontario--(Newsfile Corp. - March 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering ("Offering") of units ("Units").
On closing, the Corporation issued an aggregate of 4,230,770 Units at a price of 0.26 per Unit for aggregate gross proceeds of 1,100,000.
Each Unit consisted of one common share of the Company ("Common Share") and one common share purchase warrant ("Warrant"). Each Warrant entitles the holder to acquire an additional Common Share at an exercise price of 0.36 per share for a period of 5 years following the date of closing.
The Company plans to use the proceeds of the financing to further the Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study currently underway, working capital and general corporate purposes.
The securities referred to in this news release have not been, and will not be, registered under the United States Securities Act of 1933, as amended ("U.S. Securities Act"), or any applicable securities laws of any state of the United States, and may not be offered or sold within the United States or to, or for, the account or benefit of, U.S. persons (as such term is defined in Regulation S under the U.S. Securities Act) or persons in the United States. unless registered under the U.S. Securities Act and any other applicable securities laws of the United States or an exemption from such registration requirement is available. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of the securities offered in any jurisdiction in which such offer, solicitation or sale would be unlawful; including, the United States.
All securities issued under the Offering will be subject to a four month and one day hold period from the closing date under applicable Canadian securities laws, which expires on July 11, 2026.
The Offering is subject to receipt of final acceptance from the TSX Venture Exchange.
Related Party Transactions
An aggregate of 100,000 Units, representing gross proceeds of $26,000 were issued to certain insiders of the Corporation. Pursuant to Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") and TSX Venture Exchange Policy 5.9, such insider subscriptions are a "related party transaction." The Corporation is exempt from the formal valuation requirement of MI 61-101 in connection with the insider subscriptions in reliance on section 5.5(b) of MI 61-101, as no securities of the Corporation are listed or quoted for trading on the Toronto Stock Exchange, the New York Stock Exchange, the American Stock Exchange, the NASDAQ stock market or any other stock exchange outside of Canada or the United States. Additionally, the Corporation is exempt from obtaining minority shareholder approval in connection with the insider subscriptions in reliance on section 5.7(1)(a) of MI 61-101 as the aggregate value of the insider subscriptions does not exceed 25% of the market capitalization of the Corporation. Due to the limited time between the launch and the close of the Offering, there will be less than 21 days between the date the Corporation files its material change report in respect of the Offering and the completion date of the Offering.
About Theralase® Technologies Inc.:
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses.
Additional information is available at www.theralase.com and www.sedarplus.ca.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains Forward-Looking Statements ("FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals.
These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; access to sufficient capital to fund the Company's operations is available on terms that are commercially favorable to the Company or at all; the Company's small molecule and formulations may not be effective against the diseases tested in its clinical studies; the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.
Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.
Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.
All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS.
For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies.
For More Information:
1.866.THE.LASE (843.5273)
416.699.LASE (5273)
www.theralase.com
Kristina Hachey, CPA
Chief Financial Officer X 224
khachey@theralase.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/287848
FAQ**
How does Theralase Technologies Inc. (TLTFF) plan to allocate the $1.1 million raised in their recent private placement toward their NMIBC clinical study in Toronto?
What are the implications of the insider subscriptions in the private placement for Theralase Technologies Inc. (TLTFF) and its minority shareholders?
What challenges might Theralase Technologies Inc. (TLTFF) face in securing regulatory approvals for their research on energy-activated small molecules for cancer treatment in Canada?
Given the current market conditions, how might Theralase Technologies Inc. (TLTFF) leverage its clinical advancements to appeal to new investors in the Toronto area?
**MWN-AI FAQ is based on asking OpenAI questions about Theralase Technologies Inc. (TSXVC: TLT:CC).
NASDAQ: TLT:CC
TLT:CC Trading
-1.67% G/L:
$0.295 Last:
142,475 Volume:
$0.30 Open:
